Colchicine was associated with a modest reduction of MACE with marginal significance and high heterogeneity (7.3% vs. 8.3%; relative risk [RR] 0.73; 95% confidence interval [CI] 0.54–0.99; I 2 = 68%) compared with placebo.
← all excerpts
Colchicine Among Patients with Acute Coronary Syndrome: A Meta-Analysis of Randomized Trials.
2
—
—
The sentences
First, there was a high degree of heterogeneity among the included trials, particularly in the primary outcome, which may have influenced the pooled estimates showing a modest and marginally significant reduction in MACE in the primary analysis.